These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 12634618)

  • 1. Weekly docetaxel in patients with pretreated metastatic breast cancer: a phase II trial.
    Mey U; Gorschlüter M; Ziske C; Kleinschmidt R; Glasmacher A; Schmidt-Wolf IG
    Anticancer Drugs; 2003 Mar; 14(3):233-8. PubMed ID: 12634618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Final results of a phase II clinical trial of weekly docetaxel in combination with capecitabine in anthracycline-pretreated metastatic breast cancer.
    Mackey JR; Tonkin KS; Koski SL; Scarfe AG; Smylie MG; Joy AA; Au HJ; Bodnar DM; Soulieres D; Smith SW
    Clin Breast Cancer; 2004 Oct; 5(4):287-92. PubMed ID: 15507175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II study of weekly docetaxel in patients with anthracycline pretreated metastatic breast cancer.
    Ford HE; Yap YS; Miles DW; Makris A; Hall M; Miller L; Harries M; Smith IE; Johnston SR
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):809-15. PubMed ID: 16528527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC).
    Gervais R; Ducolone A; Breton JL; Braun D; Lebeau B; Vaylet F; Debieuvre D; Pujol JL; Tredaniel J; Clouet P; Quoix E
    Ann Oncol; 2005 Jan; 16(1):90-6. PubMed ID: 15598944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial.
    Hainsworth JD; Burris HA; Yardley DA; Bradof JE; Grimaldi M; Kalman LA; Sullivan T; Baker M; Erland JB; Greco FA
    J Clin Oncol; 2001 Aug; 19(15):3500-5. PubMed ID: 11481356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer.
    Hainsworth JD; Burris HA; Erland JB; Thomas M; Greco FA
    J Clin Oncol; 1998 Jun; 16(6):2164-8. PubMed ID: 9626217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I-II parallel study of docetaxel on a bimonthly schedule in refractory metastatic breast carcinoma.
    Gebbia V; Borsellino N; Testa A; Tirrito ML; Ferrera P; Colombo A; Mauceri G; Marrazzo A; Porretto F; Musso M
    Breast Cancer Res Treat; 2003 Jan; 77(2):99-108. PubMed ID: 12602908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer.
    Gennari A; Guarneri V; Landucci E; Orlandini C; Rondini M; Salvadori B; Ricci S; Conte PF
    Clin Breast Cancer; 2002 Dec; 3(5):346-52. PubMed ID: 12533265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors.
    Marshall J; Chen H; Yang D; Figueira M; Bouker KB; Ling Y; Lippman M; Frankel SR; Hayes DF
    Ann Oncol; 2004 Aug; 15(8):1274-83. PubMed ID: 15277270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer.
    Tabernero J; Climent MA; Lluch A; Albanell J; Vermorken JB; Barnadas A; Antón A; Laurent C; Mayordomo JI; Estaun N; Losa I; Guillem V; Garcia-Conde J; Tisaire JL; Baselga J
    Ann Oncol; 2004 Sep; 15(9):1358-65. PubMed ID: 15319242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Phase I/II clinical trial of weekly administration of docetaxel plus cisplatin for advanced non-small cell lung cancer].
    Li JL; Zhang XR; Liu JW; Chen ZY; Lin YC; Wang YD; Chen Q; Nan KJ; Song SP; Han FC; Zhu YZ; Li LY; Zheng YH; Chu DT
    Zhonghua Zhong Liu Za Zhi; 2006 Apr; 28(4):309-12. PubMed ID: 16875636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Docetaxel administered on a weekly basis for metastatic breast cancer.
    Burstein HJ; Manola J; Younger J; Parker LM; Bunnell CA; Scheib R; Matulonis UA; Garber JE; Clarke KD; Shulman LN; Winer EP
    J Clin Oncol; 2000 Mar; 18(6):1212-9. PubMed ID: 10715290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of weekly docetaxel in frail and/or elderly patients with metastatic breast cancer: a phase II study.
    D'hondt R; Paridaens R; Wildiers H; Pauwelyn K; Thomas J; Dumez H; Van Oosterom AT
    Anticancer Drugs; 2004 Apr; 15(4):341-6. PubMed ID: 15057137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of escalated-dose docetaxel with granulocyte colony-stimulating factor support in patients with advanced breast cancer.
    Mitchell PL; Basser R; Chipman M; Grigg A; Mansfield R; Cebon J; Davis ID; Appia F; Green M
    Ann Oncol; 2004 Apr; 15(4):585-9. PubMed ID: 15033663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High efficacy and low toxicity of weekly docetaxel given as first-line treatment for metastatic breast cancer.
    Stemmler J; Mair W; Stauch M; Papke J; Deutsch G; Abenhardt W; Dorn B; Kentenich C; Malekmohammadi M; Jackisch C; Leinung S; Brudler O; Vehling-Kaiser U; Stamp J; Heinemann V
    Oncology; 2005; 68(1):71-8. PubMed ID: 15809523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of weekly docetaxel in patients with metastatic breast cancer.
    Aihara T; Kim Y; Takatsuka Y
    Ann Oncol; 2002 Feb; 13(2):286-92. PubMed ID: 11886007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement of safety profile of docetaxel by weekly administration in patients with metastatic breast cancer.
    Warm M; Nawroth F; Ohlinger R; Valter M; Pantke E; Mallmann P; Harbeck N; Kates R; Thomas A
    Onkologie; 2007 Sep; 30(8-9):436-41. PubMed ID: 17848815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weekly docetaxel as second-line therapy for patients with advanced breast cancer resistant to previous anthracycline treatment.
    Ramos M; González-Ageitos A; Amenedo M; González-Quintas A; Gamazo JL; Togores P; Losada G; Almanza C; Romero C; Gómez-Martín C
    J Chemother; 2003 Apr; 15(2):192-7. PubMed ID: 12797398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A dose escalation study of weekly docetaxel in patients with advanced solid tumors.
    Kouroussis C; Agelaki S; Mavroudis D; Souglakos J; Kakolyris S; Kalbakis K; Vardakis N; Reppa D; Hatzidaki D; Samonis G; Georgoulias V
    Cancer Chemother Pharmacol; 2000; 46(6):488-92. PubMed ID: 11138462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumors: a collaborative pediatric branch, National Cancer Institute and Children's Cancer Group trial.
    Blaney SM; Seibel NL; O'Brien M; Reaman GH; Berg SL; Adamson PC; Poplack DG; Krailo MD; Mosher R; Balis FM
    J Clin Oncol; 1997 Apr; 15(4):1538-43. PubMed ID: 9193350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.